title: Apoptosis-inducing effect of the DR5 monoclonal antibody, D-6, alone             or in combination with cisplatin, on A2780 ovarian cancer cells.
abstract: Death receptor 5 (DR5) antibody (D-6) is a monoclonal antibody directed against DR5. The aim of this study was to explore the apoptosis-inducing effects of DR5 (D-6), alone or in combination with cisplatin, on A2780 ovarian cancer cells. The cells were treated with various concentrations of cisplatin and/or DR5 (D-6), or a combination of both. For the control group, the cells were treated only with culture medium. Twenty-four hours after the culture, the morphological changes of each group were observed under an inverted microscope. The cell growth inhibition rates were also analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-trazolium bromide (MTT) assays, and the apoptosis was analyzed by flow cytometry. Western blotting analysis was used to detect the intracellular reaction. Our results showed that DR5 monoclonal antibody (D-6) was able to induce the apoptosis and increase the cell growth inhibition rates of ovarian cancer cells in a dose-dependent manner, and the effect was enhanced by cisplatin. There were significant morphological changes, a higher cell growth inhibition rate and apoptosis rate and lesser expression of caspase-3, 8, 9 precursors in the cells treated with both cisplatin and DR5 (D-6). The combination treatment of the DR5 monoclonal antibody (D-6) with cisplatin may be a promising treatment for ovarian cancer.
authors.affiliation: Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China.
authors.forename: Qin
authors.initials: Q
authors.lastname: Jiang
authors.forename: Hong
authors.initials: H
authors.lastname: Zhu
authors.forename: Baoquan
authors.initials: B
authors.lastname: Liang
authors.forename: Yan
authors.initials: Y
authors.lastname: Huang
authors.forename: Chunmei
authors.initials: C
authors.lastname: Li
mesh_terms: D000818:Animals; D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis; D015153:Blotting, Western; D053181:Caspase 8 / Q000378:metabolism; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology*; D003470:Culture Media / Q000378:metabolism; D004354:Drug Screening Assays, Antitumor; D005260:Female; D005434:Flow Cytometry; D051379:Mice; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000276:immunology*; D015398:Signal Transduction; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism; D013778:Tetrazolium Salts / Q000378:metabolism; D013844:Thiazoles / Q000378:metabolism
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D003470:Culture Media; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D053221:TNF-Related Apoptosis-Inducing Ligand; D013778:Tetrazolium Salts; D013844:Thiazoles; C505526:Casp8 protein, mouse; D053181:Caspase 8; C022616:thiazolyl blue; D002945:Cisplatin